Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

BERLIN, Sept. 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).  The data were presented in an oral presentation at the International Liver Cancer Association (ILCA) Annual Meeting in Berlin, Germany, by Mong Cho, M.D., from Pusan National University Yangsan Hospital, South Korea.

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intra-tumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

The primary objective of this study was to determine the safety of JX-594 followed by sorafenib in patients with advanced HCC. The sequential treatment regimen was well tolerated with transient flu-like symptoms and transient leukopenia being the most common side effects related to JX-594.  The sorafenib side effects observed were consistent with the expected toxicity profile of this product.

Secondary endpoints included the effect of the sequential treatment of JX-594 followed by sorafenib on disease control and tumor response. Evidence of antitumor activity was observed in both sorafenib-naive and sorafenib-refractory patients. 

Importantly, this trial also demonstrated the feasibility of the systemic administration of the product (through intravenous injection).

"Our ability to deliver JX-594 intravenously to liver cancer tumors, further confirmed by these encouraging data, is a key attribute that sets it apart from other thera
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 CVS Health ... conference call on Friday, May 1, 2015, at 8:30 ... first quarter financial results. An audio webcast ... the Investor Relations portion of the CVS Health website ... http://investors.cvshealth.com . This webcast will be archived and ...
(Date:4/17/2015)... , April 17, 2015  Trovagene, Inc., ... announced today that clinical data presented at the ... its urine-based Precision Cancer Monitoring ℠ (PCM) ... monitoring of EGFR T790M mutations in ... Detection of EGFR T790M Mutation in Urinary Circulating ...
(Date:4/17/2015)... YORK , April 17, 2015  Over the next ... to continue to grow, with ArcView predicting that 14 more ... legalize medical marijuana. The U.S. market for legal cannabis grew ... billion in 2013. Analysts project the market could grow more ... assuming more states soften their stance on marijuana. ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... 9, 2011 Reportlinker.com announces that a new ... Omega-3-acid ethyl esters - Comprehensive ... Eliminate unnecessary risk with the industry ... Developer is a regularly updated, professional patent search ...
... Telik, Inc. (Nasdaq: TELK ) today announced that ... overview at the 13th Annual BIO CEO & Investor Conference ... p.m. Eastern time (12:00 p.m. Pacific time), in the Waldorf-Astoria ... presentation will be available on the Telik website, www.telik.com ...
Cached Medicine Technology:Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 2Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 3Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 4
(Date:4/18/2015)... 2015 Review of Ophthalmology magazine and ... for Success’ program for cataract surgeons attending the American ... Diego, where eye surgeon Jeffrey L. Martin, MD will ... Dr. Martin is the Managing Partner of North Shore ... Dr. Martin to lead this year’s discussion on the ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
(Date:4/18/2015)... NC (PRWEB) April 18, 2015 Patients ... risk of developing mesothelioma later in life, but the ... from mesothelioma that is unrelated to radiation. Surviving Mesothelioma ... on its website. Click here to read it ... Australia compared the cases of 45 patients who had ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... New York, NY (PRWEB) April 18, 2015 ... their Internal Security Threat Report , which they say, “exposes ... on how many new malware variants were introduced in 2014 ... it took for Zero Day threats to be identified and ... – it is abundantly clear that doing business in a ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... and money to properly treat a growing number of ... report out Friday . ,"The military system ... adequately support the psychological health of service members and ... year-long Pentagon mental health task force report: "An Achievable ...
... an industrial chemical found in anti-freeze into its products ... potentially dangerous substance . ,Shanghai White Cat, ... financial hub's oldest companies, said in a statement released ... diethylene glycol, or DEG. The Shanghai-listed firm said the ...
... car rental service to reduce pollution and traffic in the capital, ... of eco-friendly vehicles will be made available before the end of ... be dropped off at various sites set up in Paris, Delanoe ... ,"The idea is that you won't have to use a car ...
... Bordeaux next week safe in the knowledge that the number ... United States and in emerging markets such as China, ... 144 nations and opens June 18, is also comforted by ... thus driving up prices. A survey carried out for Vinexpo ...
... Tens of thousands Saturday staged the Gay Pride parade ... to grant homosexual couples legal status and override Vatican ... which included transvestites and lawmakers, marched under a baking ... of Saint John Lateran, the official ecclesiastical seat of ...
... be getting back together. ,The singer is said ... the sake of their two young sons - Sean Preston and ... now talking things through and that Britney has spent two nights ... want two divorces behind her at her age. She and ...
Cached Medicine News:Health News:War Veterans Lack Adequate Mental Health Care: Pentagon Report 2Health News:Wine Woos World as Trade Fair Opens 2Health News:Wine Woos World as Trade Fair Opens 3Health News:Gay Pride Attracts Tens of Thousands in Rome 2
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: